Target- |
MechanismPhotosensitizers |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date29 Sep 2016 |
口服盐酸氨酮戊酸口服溶液用粉末对恶性脑胶质瘤进行光动力诊断的III期临床试验
[Translation] Phase III clinical trial of oral aminolevulinic acid hydrochloride oral solution and powder for photodynamic diagnosis of malignant brain glioma
评价恶性高级别(WHO 3~4 级)脑胶质瘤患者单次口服盐酸氨酮戊酸口服溶液用粉末(5-ALA)用于荧光引导下肿瘤切除术的有效性和安全性。
[Translation] To evaluate the efficacy and safety of a single oral dose of aminolevulinic acid hydrochloride powder for oral solution (5-ALA) for fluorescence-guided tumor resection in patients with malignant high-grade (WHO grade 3-4) brain glioma.
奥贝胆酸片治疗原发性胆汁性胆管炎的有效性和安全性的多中心、随机、双盲双模拟、安慰剂对照桥接临床试验
[Translation] A multicenter, randomized, double-blind, double-dummy, placebo-controlled bridging clinical trial to evaluate the efficacy and safety of obeticholic acid tablets in the treatment of primary biliary cholangitis
评价奥贝胆酸片对比安慰剂治疗中国原发性胆汁性胆管炎患者的有效性和安全性。
[Translation] To evaluate the efficacy and safety of obeticholic acid tablets compared with placebo in the treatment of Chinese patients with primary biliary cholangitis.
[Translation] A post-marketing safety evaluation study of T0004 in the treatment of port-wine stains
在临床应用真实使用条件下观察T0004的少见不良反应,进一步评价药物的安全性。
[Translation] Observe the rare adverse reactions of T0004 under real clinical usage conditions and further evaluate the safety of the drug.
100 Clinical Results associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
100 Deals associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.